Pancreatic Cancer Research

ResearcherBrighton and Sussex Medical SchoolActive in the last 2 years

Gordon A. Ferns

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0957-8349; OpenAlex author ID A5038854437. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers

Papers 11

  1. Microbiome as a biomarker and therapeutic target in pancreatic cancer. Co-author DOI 10.1186/s12866-023-03166-4↗
  2. Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy. First author DOI 10.2174/0115680096279288231205105904↗
  3. Down regulation of Cathepsin W is associated with poor prognosis in pancreatic cancer. Co-author DOI 10.1038/s41598-023-42928-y↗
  4. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer. Co-author DOI 10.2174/0113894501264450231129042256↗
  5. Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers as Potential Therapeutic Options for Pancreatic Cancer. Last author DOI 10.2174/1568009622666220517104411↗
  6. Association of a Genetic Variant in the Cyclin-Dependent Kinase Inhibitor 2B with Risk of Pancreatic Cancer. Co-author DOI 10.52547/rbmb.11.2.336↗
  7. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2021.119118↗
  8. PNU-74654 enhanced the antiproliferative activity of gemcitabine via targeting Wnt/β-catenin Pathway in Pancreatic cancer Co-author DOI 10.21203/rs.3.rs-881431/v1↗
  9. Therapeutic potential of targeting the Wnt/β-catenin pathway in the treatment of pancreatic cancer. Co-author DOI 10.1002/jcb.27835↗
  10. Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.2174/1381612825666190110145855↗
  11. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer. Co-author DOI 10.2174/0929867324666170206142658↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Majid Khazaei · 8 shared papers, 2019–2024 · strength 1.15
  2. Amir Avan · 7 shared papers, 2017–2024 · strength 0.84
  3. Ghazaleh Pourali · 3 shared papers, 2023–2024 · strength 0.50
  4. Amir Avan · 3 shared papers, 2022–2023 · strength 0.49
  5. Majid Ghayour‐Mobarhan · 3 shared papers, 2017–2024 · strength 0.40
  6. Mohsen Aliakbarian · 2 shared papers, 2022–2024 · strength 0.36
  7. Fatemeh Khojasteh‐Leylakoohi · 2 shared papers, 2022–2023 · strength 0.27
  8. Mohammad‐Hassan Arjmand · 1 shared paper, 2024 · strength 0.23
  9. Rozita Khodashahi · 1 shared paper, 2024 · strength 0.23
  10. Fereshteh Asgharzadeh · 1 shared paper, 2022 · strength 0.17
  11. Zahra Yousefli · 1 shared paper, 2023 · strength 0.14
  12. Alfred King-yin Lam · 1 shared paper, 2023 · strength 0.14
  13. Elisa Giovannetti · 1 shared paper, 2023 · strength 0.14
  14. Negar Khoshghamat · 1 shared paper, 2021 · strength 0.13
  15. Newsha Sardarzade · 1 shared paper, 2022 · strength 0.13
  16. Sajjad Sharifi · 1 shared paper, 2021 · strength 0.12
  17. Sadaf Ghanaatgar‐Kasbi · 1 shared paper, 2018 · strength 0.11
  18. Seyed Alireza Javadinia · 1 shared paper, 2019 · strength 0.09
  19. Mina Hosseini · 1 shared paper, 2017 · strength 0.07
  20. Mina Maftouh · 1 shared paper, 2017 · strength 0.07
  21. Safieh Ebrahimi · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.